{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:55:57Z","timestamp":1793890557230,"version":"4.8.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clindermatol.2025.05.004","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:02:45Z","timestamp":1747162965000},"page":"490-501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Biologic therapies and small molecules in the treatment of hidradenitis suppurativa"],"prefix":"10.1016","volume":"43","author":[{"given":"De\u0161a","family":"Te\u0161anovi\u0107 Perkovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branka","family":"Marinovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Te\u0161anovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zrinka","family":"Bukvi\u0107 Mokos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2025.05.004_bib0001","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/jid.2012.255","article-title":"Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota","volume":"133","author":"Vazquez","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0002","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2018.02965","article-title":"Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model","volume":"9","author":"Vossen","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0003","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jamadermatol.2020.3630","article-title":"Contribution of genetics to the susceptibility to hidradenitis suppurativa in a large, cross-sectional dutch twin cohort","volume":"156","author":"van Straalen","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0004","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/hmg\/ddy414","article-title":"Analysis of hidradenitis suppurativa\u2013linked mutations in four genes and the effects of PSEN1-P242LfsX11 on cytokine and chemokine expression in macrophages","volume":"28","author":"Li","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000018126","article-title":"Cigarette Smoking as a Triggering Factor of Hidradenitis suppurativa","volume":"198","author":"K\u00f6nig","year":"1999","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0006","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s13555-024-01169-1","article-title":"Topical and systemic retinoids in the management of hidradenitis suppurativa: a comprehensive literature review","volume":"14","author":"Molinelli","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0007","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaad.2009.02.013","article-title":"Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity","volume":"61","author":"Canoui-Poitrine","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0008","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.jaad.2015.07.045","article-title":"Pathophysiology of hidradenitis suppurativa: an update","volume":"73","author":"Prens","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0009","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/bjd.14992","article-title":"Hidradenitis suppurativa: a disease of infundibular epidermis rather than pilosebaceous units?","volume":"176","author":"Janse","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0010","first-page":"260","article-title":"T helper 17 cell\/regulatory T-cell imbalance in hidradenitis suppurativa\/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities","volume":"179","author":"Melnik","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0011","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.jid.2020.01.023","article-title":"Lesional inflammatory profile in hidradenitis suppurativa is not solely driven by IL-1","volume":"140","author":"Vossen","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0012","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/bjd.17508","article-title":"Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment","volume":"180","author":"Rondags","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0013","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/jdv.20472","article-title":"European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: treatment","volume":"39","author":"Zouboulis","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0014","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/bjd\/ljad345","article-title":"Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape","volume":"190","author":"Krueger","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0015","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0016","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0017","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1111\/jdv.16642","article-title":"Validity of EQ-5D-5L, Skindex-16, DLQI and DLQI-R in patients with hidradenitis suppurativa","volume":"34","author":"Gergely","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0018","doi-asserted-by":"crossref","first-page":"137","DOI":"10.23736\/S0392-0488.18.06021-2","article-title":"Patient-reported outcomes in hidradenitis suppurativa","volume":"154","author":"Vellaichamy","year":"2019","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0019","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cei.13449","article-title":"IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa","volume":"201","author":"Fletcher","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0020","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00403-017-1769-5","article-title":"IL-36 cytokines are increased in acne and hidradenitis suppurativa","volume":"309","author":"Di Caprio","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0021","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0022","doi-asserted-by":"crossref","first-page":"155585","DOI":"10.1016\/j.cyto.2021.155585","article-title":"Serum high-sensitivity C-reactive protein, tumor necrosis factor-\u03b1, interleukin (IL)-1\u03b2, IL-17A and IL-23 levels in patients with hidradenitis suppurativa","volume":"144","author":"Sara\u00e7 \u00d6zt\u00fcrk","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0023","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.12688\/f1000research.17267.1","article-title":"A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa","volume":"7","author":"Frew","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0024","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/biomedicines10061303","article-title":"Biologics and small molecule inhibitors for treating hidradenitis suppurativa: a systematic review and meta-analysis","volume":"10","author":"Huang","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0025","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjd.12341","article-title":"Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study","volume":"169","author":"Mahil","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0026","first-page":"1330","article-title":"Navigating targeted therapeutics in dermatology: biologics and small molecules","volume":"17","author":"Costello","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0027","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.3390\/ijms23073753","article-title":"Bukvi\u0107 Mokos Z. New and emerging targeted therapies for hidradenitis suppurativa","volume":"23","author":"Markota \u010cagalj","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2020.06.019","article-title":"A systematic review of promising therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance","volume":"141","author":"Frew","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0029","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2340\/00015555-0749","article-title":"Increased serum tumour necrosis factor- in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor- agents?","volume":"89","author":"Matusiak","year":"2009","journal-title":"Acta Derm Venerol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0030","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2133.2011.10339.x","article-title":"A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa","volume":"165","author":"Miller","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0031","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0032","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/bjd.17919","article-title":"Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials","volume":"181","author":"Jemec","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0033","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","article-title":"Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study","volume":"80","author":"Zouboulis","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0034","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjd.13343","article-title":"Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris","volume":"172","author":"Gniadecki","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0035","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40262-016-0502-4","article-title":"Population Pharmacokinetics and immunogenicity of adalimumab in adult patients with moderate-to-severe hidradenitis suppurativa","volume":"56","author":"Nader","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0036","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40257-020-00579-z","article-title":"Is there a role for therapeutic drug monitoring in patients with hidradenitis suppurativa on tumor necrosis factor-\u03b1 inhibitors?","volume":"22","author":"Abdalla","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0037","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjd.18983","article-title":"Evidence for a \u2018window of opportunity\u2019 in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study","volume":"184","author":"Marzano","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0038","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11886-018-1067-7","article-title":"Tumor necrosis factor-\u03b1 in heart failure: an updated review","volume":"20","author":"Schumacher","year":"2018","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0039","first-page":"241","article-title":"Current systemic treatment strategies for hidradenitis suppurativa","volume":"5","author":"Ponikowska","year":"2017","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0040","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/1744666X.2016.1221762","article-title":"Adalimumab for the treatment of hidradenitis suppurativa\/acne inversa","volume":"12","author":"Zouboulis","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0041","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","author":"Toussirot","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0042","series-title":"StatPearls. NCBI Bookshelf version","author":"Fatima","year":"2024"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0043","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jdv.15233","article-title":"Hidradenitis suppurativa\/acne inversa: a practical framework for treatment optimization \u2013 systematic review and recommendations from the HS ALLIANCE working group","volume":"33","author":"Zouboulis","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0044","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0045","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jaad.2019.09.071","article-title":"High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa","volume":"82","author":"Ghias","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0046","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jaad.2019.05.022","article-title":"Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa","volume":"81","author":"Oskardmay","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0047","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/bjd.12713","article-title":"Four-weekly infliximab in the treatment of severe hidradenitis suppurativa","volume":"170","author":"Moriarty","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0048","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneurol.2009.11","article-title":"Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-\u03b1\u2013blocker therapy","volume":"66","author":"Lozeron","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0049","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1128\/JCM.06161-11","article-title":"Gemella morbillorum bacteremia after anti-tumor necrosis factor alpha as acne inversa therapy","volume":"50","author":"Vossen","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0050","doi-asserted-by":"crossref","DOI":"10.5070\/D3203021764","article-title":"A case of a patient with stage III familial hidradenitis suppurativa treated with 3 courses of infliximab and died of metastatic squamous cell carcinoma","volume":"20","author":"Scheinfeld","year":"2014","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0051","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jamadermatol.2021.0220","article-title":"Comparing the effectiveness and safety associated with infliximab vs infliximab-abda therapy for patients with hidradenitis suppurativa","volume":"157","author":"Westerkam","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0052","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0053","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jaad.2019.09.012","article-title":"Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: A retrospective chart review","volume":"82","author":"Wang","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0054","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations part I: diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090284","article-title":"IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model","volume":"9","author":"Chiricozzi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0056","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1002\/eji.200939687","article-title":"The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: A novel immunological cascade with potential relevance in psoriasis","volume":"39","author":"Wolk","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0057","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.jid.2017.05.033","article-title":"Hidradenitis suppurativa is characterized by dysregulation of the th17:treg cell axis, which is corrected by anti-tnf therapy","volume":"137","author":"Moran","year":"2017","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0058","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0060","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0061","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0062","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jaad.2020.05.007","article-title":"The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study","volume":"83","author":"Frew","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0063","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0064","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jaad.2019.03.056","article-title":"A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti\u2013interleukin 17A\/F nanobody, in moderate-to-severe psoriasis","volume":"81","author":"Svecova","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0066","unstructured":"National Library of Medicine. A Study to Test the Efficacy and Safety of SAR442970 in Adults with Hidradenitis Suppurativa (HS OBTAIN). Available at: https:\/\/clinicaltrials.gov\/study\/NCT05849922. Accessed February 22, 2025"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0067","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/ajt.15661","article-title":"First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody","volume":"20","author":"Espi\u00e9","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0068","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0069","unstructured":"National Library of Medicine. Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03827798. Accessed February 22, 2025."},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0070","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jaci.2022.10.034","article-title":"Neutrophilic granulocyte-derived B-cell activating factor supports B cells in skin lesions in hidradenitis suppurativa","volume":"151","author":"Sabat","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0071","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186744","article-title":"Hidradenitis suppurativa: key insights into treatment success and failure","volume":"134","author":"van Straalen","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0072","unstructured":"National Library of Medicine. Hidradenitis Suppurativa Phase 2b Study of Izokibep. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05355805. Accessed February 22, 2025."},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0073","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.35","article-title":"Affibody molecules as engineered protein drugs","volume":"49","author":"Frejd","year":"2017","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0074","unstructured":"National Library of Medicine. Hidradenitis Suppurativa Study of Izokibep. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05905783. Accessed February 22, 2025."},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0075","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/bjd\/ljae144","article-title":"Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial","volume":"191","author":"Alavi","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0076","unstructured":"National Library of Medicine. A Study of LY3041658 in Adults With Hidradenitis Suppurativa. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04493502. Accessed February 22, 2025."},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0077","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaad.2013.09.044","article-title":"An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa","volume":"70","author":"Leslie","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0078","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a Randomized Clinical Trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0079","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1111\/jdv.19252","article-title":"Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized study","volume":"37","author":"Kimball","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0080","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1468-3083.2011.04123.x","article-title":"Experience with ustekinumab for the treatment of moderate to severe Hidradenitis suppurativa","volume":"26","author":"Gulliver","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0081","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1684\/ejd.2019.3663","article-title":"High-dosage ustekinumab for the treatment of severe hidradenitis suppurativa","volume":"29","author":"Scholl","year":"2019","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0082","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000501075","article-title":"Ustekinumab with intravenous infusion: results in hidradenitis suppurativa","volume":"236","author":"Roman\u00ed","year":"2020","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0083","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s13555-024-01207-y","article-title":"Ustekinumab in hidradenitis suppurativa: a systematic review and meta-analysis","volume":"14","author":"Masson","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0084","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/12034754231154261","article-title":"utility of rituximab in the treatment of hidradenitis suppurativa: a systematic review","volume":"27","author":"Seigel","year":"2023","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0085","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1111\/1346-8138.14144","article-title":"Successful treatment of hidradenitis suppurativa with rituximab for a patient with idiopathic carpotarsal osteolysis and chronic active antibody-mediated rejection","volume":"45","author":"Takahashi","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0086","unstructured":"Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3. Available at: https:\/\/news.abbvie.com\/2024-01-08-Lutikizumab-Showed-Positive-Results-in-a-Phase-2-Trial-of-Adults-with-Moderate-to-Severe-Hidradenitis-Suppurativa-as-Program-Advances-to-Phase-3. Accessed February 22, 2025."},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0087","unstructured":"National Library of Medicine. A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Na\u00efve to Biologic Therapy. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05139602?rank=1. Accessed February 22, 2025"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0088","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s13555-023-00913-3","article-title":"Efficacy and safety of risankizumab for the treatment of hidradenitis suppurativa: a phase 2, randomized, placebo-controlled trial","volume":"13","author":"Kimball","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0089","unstructured":"National Library of Medicine. Efficacy and safety study of BDB-001 injection in patients with moderate to severe hidradenitis suppurativa (HS). Available at: https:\/\/clinicaltrials.gov\/study\/NCT05093855. Accessed February 22, 2025."},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0090","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1073\/pnas.0813037106","article-title":"Prevention of autoimmune disease by induction of tolerance to toll-like receptor 7","volume":"106","author":"Hayashi","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0091","article-title":"BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7\/8) agonist, in combination with pembrolizumab in advanced solid tumors: phase 1 safety and efficacy results","volume":"39","author":"Patel","year":"2021","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0092","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/eji.201646680","article-title":"Targeting JAK\/STAT signalling in inflammatory skin diseases with small molecule inhibitors","volume":"47","author":"Welsch","year":"2017","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0093","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jaad.2023.10.034","article-title":"Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study","volume":"90","author":"Kirby","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0094","unstructured":"National Library of Medicine. A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) (STOP-HS2). Available at: https:\/\/clinicaltrials.gov\/study\/NCT05620836. Accessed February 22, 2025."},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0095","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300155","article-title":"Brepocitinib, zimlovisertib, and ropsacitinib in hidradenitis suppurativa","volume":"3","author":"Kimball","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0096","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1080\/17460441.2021.1948998","article-title":"Drug discovery strategies for novel leukotriene A4 hydrolase inhibitors","volume":"16","author":"R\u00f6hn","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0097","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","article-title":"Discovery of LOU064 (Remibrutinib), a potent and highly selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"63","author":"Angst","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0098","unstructured":"National Library of Medicine. A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04430855. Accessed February 22, 2025."},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0099","unstructured":"National Library of Medicine. A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS). Available at: https:\/\/clinicaltrials.gov\/study\/NCT05889182?rank=1. Accessed February 22, 2025."},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0100","unstructured":"National Library of Medicine Study. Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05635838. Accessed February 22, 2025."},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0101","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0102","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.942838","article-title":"Post-Translational modifications in atopic dermatitis: current research and clinical relevance","volume":"10","author":"Ma","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0103","unstructured":"CenterWatch. Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa. Available at: https:\/\/www.centerwatch.com\/clinical-trials\/listings\/NCT05020730\/trial-to-determine-the-immunomodulatory-activity-of-ptm-001-in-patients-with-hidradenitis-suppurativa. Accessed February 22, 2025."},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0104","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial","volume":"80","author":"Vossen","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0105","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2020.08.113","article-title":"Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders","volume":"85","author":"Aarts","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0106","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/jdv.19770","article-title":"Orismilast for the treatment of mild to severe hidradenitis suppurativa: week 16 data from OSIRIS, a phase 2a, open-label, single-centre, single-arm, dose-finding clinical trial","volume":"38","author":"Frederiksen","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0107","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ad.2023.05.015","article-title":"Narrative review and update on biologic and small molecule drugs for hidradenitis suppurativa: an entity with a promising future","volume":"114","author":"Mansilla-Polo","year":"2023","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0108","unstructured":"National Library of Medicine. Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA). Available at: https:\/\/clinicaltrials.gov\/study\/NCT03852472. Accessed February 22, 2025."},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0109","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/bjd.20880","article-title":"HSP90 inhibitor RGRN-305 for oral treatment of plaque-type psoriasis: efficacy, safety and biomarker results in an open-label proof-of-concept study","volume":"186","author":"Bregnh\u00f8j","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jamadermatol.2023.4800","article-title":"Efficacy and safety of the heat shock protein 90 inhibitor RGRN-305 in hidradenitis suppurativa: a parallel-design double-blind trial","volume":"160","author":"Ben Abdallah","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0111","unstructured":"National Library of Medicine. Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04989517. Accessed February 22, 2025."},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0112","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.3390\/ijms19123851","article-title":"The role of the aryl hydrocarbon receptor (ahr) in immune and inflammatory diseases","volume":"19","author":"Neavin","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0113","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jaad.2023.05.076","article-title":"A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa","volume":"89","author":"Jepsen","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0114","unstructured":"National Library of Medicine. Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05040698. Accessed February 22, 2025."},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0115","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/bjd\/ljad013","article-title":"CSL324, a granulocyte colony-stimulating factor receptor antagonist, blocks neutrophil migration markers that are upregulated in hidradenitis suppurativa","volume":"188","author":"Gamell","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0116","unstructured":"National Library of Medicine. Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03972280. Accessed February 22, 2025."},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0117","unstructured":"National Library of Medicine. A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06411899. Accessed February 22, 2025."},{"key":"10.1016\/j.clindermatol.2025.05.004_bib0118","unstructured":"National Library of Medicine. Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05819398?tab=history&a=6. Accessed February 22, 2025."}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X25001464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X25001464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:39:50Z","timestamp":1753234790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X25001464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":116,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0738081X25001464"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2025.05.004","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic therapies and small molecules in the treatment of hidradenitis suppurativa","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2025.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}